Skip to main content
    C

    Champions Oncology Inc (CSBR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.61
    -0.07 (-1.50%)

    Market Cap: $65.14M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Champions Oncology Inc (CSBR) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Champions Oncology (CSBR) has a market cap of $65.14M and an enterprise value of $60.78M. It earned -$1.14M on revenue of $60.66M over the last 12 months.

    Total Valuation

    Enterprise value is 6.69% below the market cap, as cash exceeds debt.

    Market Cap$65.14M
    Enterprise Value$60.78M
    Latest price (Nov 17, 2026)$4.61

    Key Dates

    The next earnings report is expected on Dec 15, 2026, covering the quarter ending Oct 31, 2026.

    Next Earnings DateDec 15, 2026 (expected)
    Last Earnings DateSep 10, 2026
    Fiscal Year EndApril

    Share Statistics

    The share count grew 0.96% a year over 3 years.

    Shares Outstanding13.90M
    Shares Change (YoY)+0.79%
    Share Count Growth (3Y CAGR)+0.96%

    Valuation Ratios

    Sales and book value multiples are 1.1x and 16.5x. Its year-end P/S ranged from 1.1x to 3.8x from 2016 to 2025.

    P/S Ratio1.1x
    Forward P/S1.0x
    P/B Ratio16.5x
    P/TBV Ratio18.0x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 135.4x EBITDA.

    EV / Sales1.0x
    EV / EBITDA135.4x

    Price Statistics

    The stock is down 32.21% over 52 weeks and trades 5.53% below its 50-day average.

    Beta (1Y)0.38
    52-Week Change-32.21%
    1-Month Change-1.71%
    3-Month Change-6.68%
    6-Month Change-22.91%
    5-Year Change-50.77%
    10-Year Change+204.43%
    Total Return (1Y)-32.21%
    Total Return (3Y CAGR)-5.54%
    Total Return (5Y CAGR)-13.87%
    Return vs SPY (1Y)-44.26%
    Max Drawdown (1Y)-40.90%
    Max Drawdown (3Y)-60.60%
    Sharpe Ratio (1Y)-0.75
    Correlation with SPY (1Y)0.10
    50-Day Average$4.88
    200-Day Average$5.60
    52-Week Range$4.52 to $8.31
    RSI (14 Days)38.8
    Average Volume (20 Days)7.23K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.03x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio1.03x
    Quick Ratio1.03x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -29.15% and return on assets is -3.41% over the last 12 months.

    Return on Equity (ROE)-29.15%
    Return on Assets (ROA)-3.41%
    Return on Capital Employed (ROCE)-6.13%
    ROA (5Y Average)-6.33%
    ROIC (5Y Average)49.53%
    Asset Turnover1.90x
    Receivables Turnover4.53x

    Scores

    CSBR has an Altman Z-Score of -0.34, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-0.34
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $60.66M over the last 12 months is up 6.65% from the 12 months before.

    Revenue$60.66M
    Revenue Growth (YoY)+6.65%
    Gross Profit$30.22M
    Operating Income-$1.02M
    Pretax Income-$892.00K
    Net Income-$1.14M
    EBITDA$441.00K
    EBIT-$892.00K
    Reported EPS (TTM)-$0.04

    Trailing 12 months through Jul 31, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 11.69% of the $33.29M in total assets.

    Cash and Equivalents$4.36M
    Total Debt$0
    Net Cash$4.36M
    Net Cash Per Share$0.31
    Working Capital$563.00K
    Shareholder Equity$3.89M
    Book Value Per Share$0.28
    Tangible Book Value$3.56M
    Tangible Book Per Share$0.26
    Total Assets$33.29M
    Total Liabilities$28.83M

    Balance sheet as of Jul 31, 2026.

    Full balance sheet

    Cash Flow

    After $573.00K of capital spending, operating cash flow left -$6.14M of free cash flow.

    Operating Cash Flow-$5.56M
    Capital Expenditures$573.00K
    Free Cash Flow-$6.14M
    FCF Per Share-$0.44
    Depreciation and Amortization$1.33M

    Trailing 12 months through Jul 31, 2026.

    Full cash flow statement

    Margins

    The operating margin is -1.68%, against a 5-year average of -3.42%.

    Gross Margin49.82%
    Operating Margin-1.68%
    Pretax Margin-1.47%
    Net Margin-1.87%
    EBITDA Margin0.73%
    EBIT Margin-1.47%
    FCF Margin-10.12%
    Gross Margin (5Y Average)47.32%
    Operating Margin (5Y Average)-3.42%
    Net Margin (5Y Average)-3.40%

    Growth

    Revenue grew 3.33% a year over 3 years.

    Revenue Growth (3Y CAGR)+3.33%
    Revenue Growth (5Y CAGR)+7.68%
    EPS Growth (5Y CAGR)-24.40%

    Revenue and profit by year

    Dividends and Yields

    CSBR does not pay a dividend. Its free cash flow yield is -9.58%.

    FCF Yield-9.58%
    Shareholder Yield0.00%

    Stock Splits

    The last split was a 1-for-12 reverse split on Aug 12, 2015.

    Last Split DateAug 12, 2015
    Split TypeReverse split
    Split Ratio1:12

    Peer Position

    Against 5 similar companies, CSBR has the lowest P/S.

    P/S Ratio1.1x vs 12.4x median
    Revenue Growth (Trailing 4 Quarters, YoY)+6.65% vs -42.77% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 9.83% and EPS growth at 910.10% a year over the next fiscal year.

    Revenue Growth Forecast (1Y CAGR)+9.83%
    EPS Growth Forecast (1Y CAGR)+910.10%

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About CSBR

    What is CSBR's market cap?

    Champions Oncology has a market cap of $65.14M. Its enterprise value, which adds debt and subtracts cash, is $60.78M.

    How many shares of CSBR are outstanding?

    Champions Oncology has 13.90M shares outstanding. The count is up 0.79% from a year earlier.

    Does CSBR pay a dividend?

    No. Champions Oncology does not pay a dividend.

    How much debt does CSBR have?

    Champions Oncology has $0 of total debt and $4.36M of cash and equivalents, a net cash position of $4.36M.